Genmab | GEN - Current Liabilities

Stock Price
1,853.50
Daily Change
62.00 3.46%
Monthly
-11.23%
Yearly
17.09%
Q1 Forecast
1,757.86

Genmab reported DKK629M in Current Liabilities for its fiscal quarter ending in June of 2025.





Current Liabilities Change Date
Agios Pharmaceuticals USD 82.21M 7.45M Dec/2025
Almirall EUR 298.52M 54.91M Jun/2025
Amarin USD 182.23M 3.71M Sep/2025
Amgen USD 25.49B 3.7B Dec/2025
argenx SE USD 1.04B 371.99M Jun/2025
AstraZeneca USD 30.62B 3.44B Dec/2025
Bayer EUR 28.96B 825M Sep/2025
BioMarin Pharmaceutical USD 798.44M 114.19M Sep/2025
Demant DKK 7.42B 1.63B Dec/2025
Exelixis USD 405.64M 31.86M Dec/2025
Fresenius Medical Care EUR 5.76B 98.85M Sep/2025
Galapagos EUR 366.56M 36.39M Sep/2025
Genmab DKK 629M 127M Jun/2025
GlaxoSmithKline GBP 21.39B 57M Dec/2025
GN Store Nord DKK 7.32B 153M Dec/2025
GRIFOLS EUR 2.15B 164.7M Sep/2025
Hikma Pharmaceutical USD 2.06B 78M Jun/2025
Insmed USD 468.87M 51.66M Dec/2025
Lonza CHF 3.58B 970M Dec/2024
Merck EUR 8.64B 1.22B Sep/2025
Novartis USD 32B 286M Sep/2025
Regeneron Pharmaceuticals USD 4.37B 56.7M Dec/2025
Roche Holding CHF 28B 421M Dec/2025
Sanofi EUR 28.35B 3.76B Dec/2025
UCB EUR 3.53B 731M Dec/2024